Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

...

Yesterday, Syneron Medical Ltd (ELOS) announced that it would buy Candela Corp. (CLZR) in a $65 million all-stock transaction. The merger is expected to be completed by year-end. It was agreed that Candela stockholders would receive 0.2911 ordinary shares of Syneron for each share of Candela. 6.7 million shares will be issued by Syneron for the acquisition at about $2.84 per share. This is 51% above Candela’s Tuesday closing price of $1.88. Therefore, the merger is of financial benefit to Candela stockholders. The merger will result in two medical laser technology providers for aesthetic treatments such as hair removal, wrinkle reduction, acne treatment etc. coming under one roof. The significant cost and product synergies resulting from the deal will increase the international exposure of the merged entity with approximately 62% revenues expected to be generated from outside the U.S. The merged entity will possess significant ...

For Immediate Release

Chicago, IL – August 31, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mylan (MYL), Sanofi-Aventis (SNY), Gilead Sciences (GILD), GlaxoSmithKline (GSK) and Freddie Mac (FRE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday’s Analyst Blog:

Mylan’s Portfolio Strengthens

We are pleased to hear that Mylan (MYL) has begun to market the generic version of BenzaClin (1% Clindamycin and 5% Benzoyl Peroxide Gel) for acne treatment, which was originally manufactured by Sanofi-Aventis (SNY). The drug has been developed under an agreement between its subsidiary,

...

We are pleased to hear that Mylan (MYL) has begun to market the generic version of BenzaClin (1% Clindamycin and 5% Benzoyl Peroxide Gel) for acne treatment, which was originally manufactured by Sanofi-Aventis (SNY). The drug has been developed under an agreement between its subsidiary, Mylan Pharmaceuticals and Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International.

Earlier this month, Dow received the US Food and Drug Administration (FDA) approval for the generic drug. Although the approval is good news for the company, we do not expect it to contribute significantly to the top line since BenzaClin had total U.S. sales of about $221 million for the 12 months ending June 30 (as per IMS data).

This is the third approval for Mylan in the month of August. A few days back, Mylan’s subsidiary Matrix Laboratories received tentative approval from the FDA under the President's Emergency Plan for AIDS Relief

...

For Immediate Release

Chicago, IL – August 27, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: United Heathcare Group (UNH), Aetna (AET), Wet Seal Inc. (WTSLA), VeriSign Inc. (VRSN) and Syniverse Holdings Inc. (SVR).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

CBO Overstates Healthcare Costs

Some of the more outrageous types of misconduct by the likes of United Heathcare Group (UNH) and Aetna (AET) might be curbed, such as the cancelling of policies as soon as someone gets sick and puts in a substantial

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Thursday July 30, 2009

PennyOmega.com Stock Report!

**************************************************************

Today Obagi Medical Products, Inc. (Nasdaq:OMPI), the leader in topical aesthetic and therapeutic skin health systems, announced the results of a meta-analysis of 23 randomized controlled clinical trials (RCTs) that compared the company’s patented solubilized 5 percent BPO (sBPO) against existing 5 percent BPO, 1-1.2 percent clindamycin (CL) and combination BPO/CL products in reducing acne lesions. The announcement was made at the American Academy of Dermatology’s (AAD) Summer Academy Meeting in Boston, Mass. The data from the meta-analysis, using data adjusted for each study’s size, shows that this new 5 percent sBPO has an equal to superior lesion reduction profile when

...

Highlights include GlaxoSmithKline plc (GSK), Johnson & Johnson (JNJ), Novartis AG (NVS) and Pfizer, Inc. (PFE).Glaxo Buys Stiefel Labs for $3.6 BillionThis morning, GlaxoSmithKline (GSK) announced it will acquire privately held Stiefel Laboratories for $2.9 billion in cash. Glaxo will also assume $400 million in debt and has agreed to pay $300 million in milestone payments depending on the performance of key assets at Stiefel, bringing the total deal size to potentially $3.6 billion.Stiefel Labs, located in Coral Cables, Florida, is the world's biggest independent dermatology company, and makes prescription and over-the-counter medications including acne treatments and other skin creams, lotions, washes and vitamins.The company had reportedly been in talks early this year to be acquired by Johnson & Johnson (JNJ) and Novartis AG (NVS). Leading products at Stiefel include Duac for acne, Olux E ...

Highlights include GlaxoSmithKline plc (GSK), Johnson & Johnson (JNJ), Novartis AG (NVS) and Pfizer, Inc. (PFE).Glaxo Buys Stiefel Labs for $3.6 BillionThis morning, GlaxoSmithKline (GSK) announced it will acquire privately held Stiefel Laboratories for $2.9 billion in cash. Glaxo will also assume $400 million in debt and has agreed to pay $300 million in milestone payments depending on the performance of key assets at Stiefel, bringing the total deal size to potentially $3.6 billion.Stiefel Labs, located in Coral Cables, Florida, is the world's biggest independent dermatology company, and makes prescription and over-the-counter medications including acne treatments and other skin creams, lotions, washes and vitamins.The company had reportedly been in talks early this year to be acquired by Johnson & Johnson (JNJ) and Novartis AG (NVS). Leading products at Stiefel include Duac for acne, Olux E ...

Medicis Pharmaceutical Corp. (MRX) slumped the most in 12 years on Wednesday after the U.S. Food and Drug Administration rejected the company's appeal for banning generic versions of its acne drug Solodyn from entering the market before the patent expired.

Mylan Inc. (MYL), Barr Laboratories Inc. and Novartis AG (NVS) unit Sandoz Inc. have submitted abbreviated new drug applications (ANDAs) for Solodyn. Israel-based Teva Pharmaceutical Industries Ltd. (TEVA) has already received a nod from federal health regulators to market its generic version of the oral antibiotic and began shipment of the product.

Medicis filed its petition for a 30-month stay on ANDAs of Solodyn, after suing all the generic makers. Solodyn, which is scheduled to lose patent protection in 2018, contributes nearly 50% of the Scottsdale, Arizona-based company's total revenue.

Shares of the company are down more than 11% today.

"MRX" Free Stock ...

Trading on the OTCBB, Euoko Group Inc. develops, markets, and distributes scientifically advanced, innovative skin treatments for luxury and mass markets. Founded in 2003, the Company has their corporate headquarters in Toronto, Ontario, Canada. They also have satellite sales offices in Milan, Italy, Chiswick, London (UK), and in Geneva, Switzerland.

Euoko, a luxury offering, is the Company’s flagship brand. Euoko Group Inc. focuses their efforts towards luxury skin-care customers. Their product portfolio consists of 25 treatments spanning five collections. These products offer comprehensive solutions to a wide range of skin concerns. The Company markets their product portfolio through premium distribution channels in over twenty countries and territories.

The Company first introduced their products in September of 2007. They have retail partnerships with premium department stores. These include Bergdorf Goodman, Saks Fifth Avenue, Neiman Marcus, La Rinascente (Italy), Ogilvy and Andrew’s (Canada), and Ludwig Beck (Germany). In addition, they have partnerships

...